Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The current COVID-19 pandemic is a worldwide healthcare crisis. Of concern is the large number of patients that are/will require mechanical ventilation, and the associated strain that this will place on healthcare resources. At present, there are no specific therapeutic interventions directed at COVID-19 infection. However, observational data suggest that there is a subgroup of patients that demonstrate a hyperinflammatory response in response to COVID-19 and have a higher requirement for Critical Care and higher mortality. There is a strong case for the use of the naturally occurring anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) in these patients. Anakinra is a recombinant form of IL-1Ra that is licensed for clinical use. Success of use of anakinra in COVID-19 trials will be greatly enhanced by robust scientific evidence and established pharmacokinetics which inform the most effective dosing regimens. The latter is especially important when, as in the case of anakinra, drug supplies are limited, the drug has short half-life and clinical ease of application is critical.
Description: Plasma IL-1Ra levels from Day 1 to Day 7 following administration of SC anakinra in patients with SARS-CoV-2
Measure: Plasma IL-1Ra levels Time: 1 weekDescription: Plasma IL-6 levels from Day 1 to Day 7 following administration of SC anakinra in patients with SARS-CoV-2
Measure: Plasma IL-6 levels Time: 1 weekDescription: Plasma markers including IL-6 from Day 1 to Day 14 in all participants
Measure: Plasma markers Time: 2 weeksDescription: Plasma markers including CRP from Day 1 to Day 14 in all participants
Measure: Plasma markers Time: 2 weeksDescription: Plasma markers including CXCL9 from Day 1 to Day 14 in all participants
Measure: Plasma markers Time: 2 weeksDescription: Plasma markers including IL-1 from Day 1 to Day 14 in all participants
Measure: Plasma markers Time: 2 weeksDescription: Plasma markers including IL-2 from Day 1 to Day 14 in all participants
Measure: Plasma markers Time: 2 weeksDescription: Plasma markers including HMBG-1 from Day 1 to Day 14 in all participants
Measure: Plasma markers Time: 2 weeksDescription: Plasma markers including IL-33 from Day 1 to Day 14 in all participants
Measure: Plasma markers Time: 2 weeksDescription: Safety endpoints include: a. Severe fatal or life-threatening serious adverse reactions (duration of IMP plus 30h from last dose).
Measure: Safety Endpoints related to the Serious adverse reactions of the IMP Time: 2 weeksDescription: Safety endpoints include: b. Anaphylactic/anaphylactoid reactions (duration of IMP plus 30h from last dose).
Measure: Safety Endpoints related to the anaphylactic reactions of the IMP Time: 2 weeksDescription: Safety endpoints include: c. Severe neutropenia (< 1.5 x 109 /L) (duration of IMP)
Measure: Safety Endpoints related to neutropenia caused by the IMP Time: 2 weeksDescription: Safety endpoints include: d. IMP related severe laboratory abnormalities (duration of IMP)
Measure: Safety Endpoints related to any severe laboratory abnormalities Time: 2 weeksDescription: Feasibility endpoints include protocol deviations in terms of timing and delivery of scheduled medication.
Measure: Feasibility endpoints related to IMP and deviations Time: 2 weeksDescription: Exploratory data on clinical efficacy as defined by: a. Time to recovery defined by hospital discharge or improvement of two points on the ordinal scale: not hospitalised; hospitalised without need for supplemental oxygen; requiring supplemental oxygen; requiring HFNC or non-invasive mechanical ventilation; requiring ECMO or mechanical intervention; dead. Improvement mechanical ventilation (from recruitment to time of ventilation)
Measure: Exploratory Data on Clinical efficacy by time to recovery Time: 4 weeksDescription: Exploratory data on clinical efficacy as defined by: b. Ventilation free days (at 28 days)
Measure: Exploratory Data on Clinical efficacy Time: 4 weeksDescription: Exploratory data on clinical efficacy as defined by: c. Status on the above ordinal scale (at 14 and 28 days)
Measure: Exploratory Data on Clinical efficacy of the ordinal scale Time: 4 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports